News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,852 Results
Type
Article (8047)
Company Profile (140)
Press Release (476664)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166773)
Career Advice (305)
Deals (25742)
Drug Delivery (7)
Drug Development (52902)
Employer Resources (14)
FDA (9770)
Job Trends (8578)
News (238297)
Policy (17940)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (487)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33162)
ALS (105)
Alzheimer's disease (976)
Antibody-drug conjugate (ADC) (264)
Approvals (10388)
Artificial intelligence (321)
ASCO (160)
Autoimmune disease (206)
Automation (28)
Bankruptcy (262)
Best Places to Work (6961)
BIO (36)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (109)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (29)
Breast cancer (510)
Cancer (3655)
Cardiovascular disease (218)
Career advice (245)
Career pathing (1)
CAR-T (174)
Celiac Disease (1)
Cell therapy (478)
Cervical cancer (34)
Clinical research (47907)
Collaboration (1247)
Commercialization (3)
Compensation (1470)
Complete response letters (34)
COVID-19 (758)
CRISPR (63)
C-suite (753)
Cystic fibrosis (85)
Data (5667)
Denatured (4)
Depression (102)
Dermatology (62)
Diabetes (344)
Diagnostics (4189)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (155)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (164)
Earnings (73719)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87642)
Executive appointments (701)
FDA (12410)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (921)
Gene editing (125)
Generative AI (9)
Gene therapy (318)
GLP-1 (290)
Government (949)
Grass and pollen (2)
Guidances (281)
Healthcare (9322)
Hematology (95)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (157)
Infectious disease (949)
Inflammatory bowel disease (127)
Inflation Reduction Act (4)
Influenza (86)
Intellectual property (255)
Interviews (41)
IPO (12387)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5196)
Licensing (8)
Liver cancer (44)
Longevity (17)
Lung cancer (509)
Lymphoma (251)
Machine learning (27)
Management (3)
Manufacturing (536)
Marketing (8)
MASH (118)
Medical device (8660)
Medtech (8805)
Mergers & acquisitions (14386)
Metabolic disorders (709)
mRNA (56)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (39)
Neuroscience (1826)
NextGen: Class of 2026 (3150)
Non-profit (842)
Obesity (225)
Opinion (10)
Ovarian cancer (159)
Pain (172)
Pancreatic cancer (197)
Parkinson's disease (201)
Partnered (12)
Patents (476)
Patient recruitment (510)
Peanut (31)
People (41245)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15473)
Phase 2 (21387)
Phase 3 (14426)
Pipeline (7356)
Policy (18)
Postmarket research (1573)
Preclinical (6540)
Press Release (34)
Prostate cancer (190)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (575)
Real estate (3019)
Recruiting (6)
Regulatory (14845)
Reports (21)
Research institute (583)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (100)
Series A (156)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (51)
Vaccines (325)
Venture capital (17)
Weight loss (73)
Women's health (79)
Date
Today (57)
Last 7 days (221)
Last 30 days (1615)
Last 365 days (19053)
2026 (12379)
2025 (19253)
2024 (22994)
2023 (26542)
2022 (34593)
2021 (37179)
2020 (33497)
2019 (23266)
2018 (17501)
2017 (18767)
2016 (17925)
2015 (24266)
2014 (21682)
2013 (18138)
2012 (20226)
2011 (20446)
2010 (20337)
Location
Africa (228)
Alabama (73)
Alaska (2)
Arizona (305)
Arkansas (11)
Asia (17909)
Australia (2098)
California (11999)
Canada (3151)
China (526)
Colorado (485)
Connecticut (410)
Delaware (208)
Europe (24650)
Florida (1791)
Georgia (382)
Hawaii (3)
Idaho (46)
Illinois (700)
India (52)
Indiana (314)
Iowa (15)
Japan (405)
Kansas (101)
Kentucky (30)
Louisiana (27)
Maine (26)
Maryland (1206)
Massachusetts (7866)
Michigan (308)
Minnesota (560)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (116)
New Hampshire (60)
New Jersey (2621)
New Mexico (12)
New York (2823)
North Carolina (1283)
North Dakota (4)
Northern California (6011)
Ohio (279)
Oklahoma (14)
Oregon (16)
Pennsylvania (2256)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4985)
Tennessee (120)
Texas (1943)
United States (38936)
Utah (361)
Vermont (1)
Virginia (153)
Washington D.C. (38)
Washington State (929)
West Virginia (1)
Wisconsin (73)
Wyoming (1)
484,852 Results for "osel inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Osel Inc. and March of Dimes Announce Groundbreaking Phase 2b Trial of Microbiome-based Therapy Targeting Preterm Birth Prevention
May 13, 2026
·
7 min read
Press Releases
Osel Enters Agreement with SWOG Cancer Research Network for First-Ever Pivotal Trial of a Microbiome-Based Therapy in Oncology
January 8, 2026
·
4 min read
Biotech Bay
Osel Obtains Exclusive License from Danish Research Consortia for IP Related to Osel’s LACTIN-V in Women Undergoing In-Vitro Fertilization
Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced that it has entered into a definitive agreement with a consortia comprising Aarhus University, Skive Hospital and Statens Serum Institut of Denmark, and obtained the exclusive worldwide license to inventions resulting from an investigator-initiated Phase 2 trial of Osel’s investigational LBP, LACTIN-V,
February 3, 2021
·
2 min read
Biotech Bay
City of Hope and Osel Announce Live Biotherapeutic Product CBM588 May Enhance Efficacy of Immunotherapy for Patients With Metastatic Kidney Cancer
City of Hope and Osel Inc. announced Phase 1 trial data showing that use of the live biotherapeutic CBM588 plus immunotherapy medicine nivolumab/ipilimumab significantly improved progression-free survival in patients with metastatic kidney cancer when compared to use of nivolumab/ipilimumab alone.
February 28, 2022
·
6 min read
Business
City of Hope and Osel Announce Exclusive License for Intellectual Property on the Use of Live Biotherapeutic Product CBM588 for Oncology Therapeutic Applications
City of Hope and Osel, Inc. today announced that City of Hope has granted an exclusive worldwide license to Osel for intellectual property on the novel use of a LBP CBM588 to enhance efficacy of checkpoint inhibitors to treat cancer, including metastatic renal cell carcinoma.
July 14, 2021
·
4 min read
Drug Development
Osel’s Live Biotherapeutic Product Demonstrates Efficacy in Phase 2b Study of Bacterial Vaginosis
Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced clinical data showing that the company’s LACTIN-V LBP significantly reduced the recurrence of bacterial vaginosis (BV) vs. placebo in a Phase 2b trial.
May 13, 2020
·
3 min read
Press Releases
City of Hope Researchers Present Advances in Targeted Therapies, Microbiome Science and Blood Cancers at ASCO 2026
May 22, 2026
·
9 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Drug Development
Osel Announces Positive Results from Phase 1b Trial of Live Biotherapeutic Product CBM588 in Combination with Checkpoint Inhibitor (CPI) Therapy in Metastatic Renal Cell Carcinoma
Osel Inc., announced today that City of Hope, a world-renowned independent cancer and diabetes research and treatment center, presented data from a Phase 1b trial showing that an LBP, CBM588 (Clostridium butyricum MIYAIRI 588® strain), plus nivolumab/ipilimumab
June 7, 2021
·
3 min read
Press Releases
FOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.
July 29, 2026
·
6 min read
1 of 48,486
Next
